Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (XTNT) is a leader in regenerative medicine, specializing in orthobiologics and spinal implant systems for complex surgical procedures. This page aggregates official company news, including product developments, financial updates, and strategic initiatives within the orthopedic and neurological sectors.
Investors and healthcare professionals will find verified press releases covering regulatory milestones, partnership announcements, and advancements in bone healing technologies. Our repository ensures access to timely updates on Xtant Medical's surgical solutions, including spinal fusion devices and biologics designed to improve patient outcomes.
Bookmark this page for direct access to earnings reports, acquisition news, and clinical trial progress. All content is sourced from official channels to maintain accuracy and compliance with financial disclosure standards.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported third quarter 2021 financial results, noting a revenue of $13.8 million, a slight decrease from $14.0 million in the prior-year period. The company experienced a net loss of $1.8 million, up from a loss of $1.4 million year-over-year. Gross margin also declined to 52.2% from 66.0%, attributed to changes in sales mix and increased write-downs of excess inventory. Operating expenses rose to $8.6 million due to higher salaries and marketing costs. Xtant continues to expand its distribution network despite challenges from the COVID-19 delta variant.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its Q3 financial results for the period ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call featuring Sean Browne, President and CEO, and Greg Jensen, CFO, is scheduled for 9:00 AM ET the same day. Investors can listen to the call via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders and offers a range of orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that CEO Sean Browne will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A pre-recorded presentation will be available on the company's website starting September 13, 2021, at 7:00 AM Eastern Time and will remain accessible for 90 days. Xtant Medical focuses on developing and commercializing spinal implant systems and orthobiologics for spinal fusion.
Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.
Xtant Medical Holdings, Inc. (XTNT) will release its financial results for Q2 2021 on August 5, 2021, before the market opens. The conference call will be hosted by CEO Sean Browne and CFO Greg Jensen at 9:00 AM ET, providing insights into the company’s performance in the spinal disorder market. Investors can access the call via dial-in or webcast, with a replay available on their website.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will have its CEO Sean Browne present at the Canaccord Musculoskeletal Conference on May 20, 2021, at 3:00 PM ET. The presentation focuses on innovations in spinal surgery solutions. Investors can access a live webcast on the company's website. A replay will be available for 90 days post-event. Xtant Medical specializes in spinal implant systems, offering comprehensive orthobiologics for complex spine procedures.
Xtant Medical Holdings, Inc. (XTNT) reported Q1 2021 results, with revenue of $12.5 million, a decrease from $14.8 million in Q1 2020, mainly due to COVID-19 impacts. Operating expenses fell to $8.1 million from $11.0 million as a result of lower sales and wages. The company incurred a net loss of $29,000, a significant improvement from $2.5 million in the prior period. Non-GAAP Adjusted EBITDA rose to $0.8 million from $0.3 million. Xtant raised $18.4 million from a private placement and secured $20 million in debt refinancing to bolster growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has filed a universal shelf registration statement on Form S-3 with the SEC, allowing the company to offer and sell various securities up to $150 million over three years. This filing is aimed at enhancing capital market access for financing growth initiatives. Additionally, it permits OrbiMed Advisors, LLC to sell up to 18,218,374 shares of XTNT common stock. The company currently has no specific plans for issuing securities under this registration, and proceeds from any stock sales will not benefit Xtant directly.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has entered into new credit agreements with MidCap Financial Trust, which include a $12 million secured term loan at 7% interest and an $8 million secured revolving credit facility at 4.5% interest. These agreements replace the existing loan from OrbiMed, fully repaying that debt. The new financing is aimed at enhancing the company's balance sheet and supporting strategic growth initiatives.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
